Skip to main content

Advertisement

SpringerLink
Log in

Amsacrine, cytarabine and etoposide in the treatment of bad prognosis acute myeloid leukemia

  • Original Articles
  • Published:
Medical Oncology and Tumor Pharmacotherapy Aims and scope Submit manuscript

Abstract

Thirty-seven patients (median age 50 yr, range 17–82) with acute myeloid leukemia (AML) received intensive induction treatment with amsacrine, cytarabine and etoposide in combination. Nine of the patients were refractory to previous induction therapy, 15 relapsed during or after treatment with daunorubicin and cytarabine, 13 had AML after previous hématologic disorders. Eleven of the patients with AML after previous hematologic disorders had been treated with cytotoxic drugs.

Toxicity was substantial, but complete remission (CR) was achieved in 33% of patients with refractory AML, 47% of patients with AML in relapse, 54% of patients with AML after antecedent blood disorder. CR duration was 15 weeks (median). Patients with AML of FAB types M4 and M5 entered remission more often (70%) than patients with other AML types (37%).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bloomfield C D: Postremission therapy in acute myeloid leukemia.J clin Oncol 3, 1570 (1985).

    PubMed  CAS  Google Scholar 

  2. Brincker H: Estimate of overall treatment results in acute nonlymphocytic leukemia based on age-specific rates of incidence and of complete remission.Cancer Treat Rep 69, 5 (1985).

    PubMed  CAS  Google Scholar 

  3. The Toronto Leukemia Study Group: Results of chemotherapy for unselected patients with acute myeloblastic leukemia: effect of exclusions on interpretation of results.Lancet i, 786 (1986).

    Google Scholar 

  4. Rosenthal D S, Moloney W C: Refractory dysmyelopoietic anemia and acute leukemia.Blood 63, 314 (1984).

    PubMed  CAS  Google Scholar 

  5. Bennett J M, Catovsky D, Daniel M-T, Flandrin G, Galton DAG, Gralnick H R, Sultan C: Proposals for the classification of the myelodysplastic syndromes.Br J Haemat 51, 189 (1982).

    CAS  Google Scholar 

  6. Bennett J M, Catovsky D, Daniel M-T, Flandrin G, Galton DAG, Gralnick H R, Sultan C: Proposals for the classification of the acute leukaemias.Br J Haemat 33, 451 (1976).

    Article  CAS  Google Scholar 

  7. Peto R, Pike M C, Armitage P, Breslow N E, Cox D R, Howard S V, Mantel N, McPherson K, Peto J, Smith P G: Design and analysis of randomized clinical trials requiring prolonged observation of each patient — II. Analysis and examples.Br J Cancer 35, 1 (1977).

    PubMed  CAS  Google Scholar 

  8. Slevin M L, Shannon M S. Prentice H G. Goldman A J, Lister T A: A phase I and II study of m-AMSA in acute leukemia.Cancer Chemother Phurmac 6, 137 (1981).

    CAS  Google Scholar 

  9. Arlin Z A, Sklaroff R B, Gee T S, Kempin S J, Howard J, Clarkson B D, Young C W: Phase I and II trial of 4′-(9-acridinylamino)methanesulfon-m-anisidide in patients with acute leukemia.Cancer Res 40, 3304 (1980).

    PubMed  CAS  Google Scholar 

  10. Legha S S, Keating M J, McCredie K B, Bodey G P, Freireich E J: Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults.Blood 60, 484 (1982).

    PubMed  CAS  Google Scholar 

  11. Bennett J M, Glick J H, Lymann G H, Oken M M, Cassileth P A: A phase II trial of VP 16-213 in adults with refractory acute myeloid leukemia.Am J clin Oncol 7, 471 (1984).

    Article  PubMed  CAS  Google Scholar 

  12. Preisler H D, Raza A, Early A. Kirshner J, Brecher M, Freeman A, Rustum Y, Azarnia N, Priore R, Sandberg A, Block A M, Browman G, Walker I, Benjer A, Miller K, D’Arrigo P, Doeblin T, Stein A, Bloom M, Logue G, Rustagi P, Barcos M, Larson R, Joyce R: High-dose cytosine arabinoside as the initial treatment of poor-risk patients with acute non-lymphocytic leukemia: a Leukemia Intergroup Study.J clin Oncol 5, 75 (1987).

    PubMed  CAS  Google Scholar 

  13. Grever M R: Treatment of patients with acute nonlymphocytic leukemia not in remission.Semin Oncol 14, 416 (1987).

    PubMed  CAS  Google Scholar 

  14. Kantarjian H M, Estey E H, Plunkett W, Keating M J, Walters R S, Lacoboni S, McCredie K B, Freireich E J: Phase I—II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia.Am J Med 81, 387 (1986).

    Article  PubMed  CAS  Google Scholar 

  15. Arlin Z A, Ahmed T, Mittelman A, Feldman E, Mehta R. Weinstein P, Rieber E, Sullivan P, Baskind P: A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia.J clin Oncol 5, 371 (1987).

    PubMed  CAS  Google Scholar 

  16. Tschopp L, von Fliedner V E, Sauter C, Maurice P, Grathwohl A, Fopp M, Cavalli F: Efficacy and clinical cross-resistance of a new combination therapy (AMSA/VP16) in previously treated patients with acute nonlymphocytic leukemia.J clin Oncol 4, 318 (1986).

    PubMed  CAS  Google Scholar 

  17. Gale R P, Foon K A: Therapy of acute myelogenous leukemia.Semin Hemat 24, 40 (1987).

    PubMed  CAS  Google Scholar 

  18. Lazzarino M, Morra E, Alessandrino E P, Inverardi D, Bernasconi P, Castagnola C, Bernasconi C: Etoposide-cytarabine therapy for acute leukemia following myelodysplastic syndromes or secondary to treatment for malignant diseases.Haematologica 72, 341 (1987).

    PubMed  CAS  Google Scholar 

  19. Cheson B D, Jasperse D M, Simon R, Friedman M A: A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes.J clin Oncol 4, 1857 (1986).

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Medicine, University Hospital, S-901 85, Umeå, Sweden

    Anders Wahlin

Authors
  1. Anders Wahlin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wahlin, A. Amsacrine, cytarabine and etoposide in the treatment of bad prognosis acute myeloid leukemia. Med. Oncol. & Tumor Pharmacother. 6, 199–205 (1989). https://doi.org/10.1007/BF02985191

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02985191

Key words

Search

Navigation